ClinicalTrials.gov
ClinicalTrials.gov Menu

Survival Outcomes of Uterine Malignancies in Chinese Population

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03291275
Recruitment Status : Recruiting
First Posted : September 25, 2017
Last Update Posted : February 8, 2018
Sponsor:
Information provided by (Responsible Party):
Lei Li, Peking Union Medical College Hospital

Brief Summary:
This study aims to determine survival outcomes (overall survival and progression-free survival) of primary uterine malignancies in China and relevant risk factors in a prospective cohort study.

Condition or disease Intervention/treatment
Endometrial Neoplasms Survival Other: Follow-up for death and recurrence

Study Type : Observational
Estimated Enrollment : 10000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Survival Outcomes of Uterine Malignancies in Chinese Population
Actual Study Start Date : September 1, 2017
Estimated Primary Completion Date : September 1, 2022
Estimated Study Completion Date : September 1, 2023

Intervention Details:
    Other: Follow-up for death and recurrence
    All patients are followed up to determine definite date of diagnosis, recurrence and death.


Primary Outcome Measures :
  1. Overall survival [ Time Frame: 5 years ]
    Survival duration from diagnosis to death

  2. Progression-free survival [ Time Frame: 5 years ]
    Survival duration from last treatment after remission to recurrence



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients with definite diagnosis of uterine malignancies in China.
Criteria

Inclusion Criteria:

  • Primary uterine malignancies.

Exclusion Criteria:

  • Metastatic malignancies to uterine corpus

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03291275


Contacts
Contact: Lei Li, MD 13911988831 ext +86 lileigh@163.com

Locations
China, China/Beiing
Lei Li Recruiting
Beijing, China/Beiing, China, 100000
Contact: Lei L Li, MD    13911988831 ext +86    lileigh@163.com   
Sponsors and Collaborators
Lei Li
Investigators
Principal Investigator: Lei Li, MD Peking Union Medical College Hospital

Responsible Party: Lei Li, Professor, Peking Union Medical College Hospital
ClinicalTrials.gov Identifier: NCT03291275     History of Changes
Other Study ID Numbers: SOUM-1
First Posted: September 25, 2017    Key Record Dates
Last Update Posted: February 8, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Diseases
Genital Diseases, Female